Prescription medicine
Somatropin Brand names: Genotropin, Norditropin, Humatrope, Serostim, Omnitrope
Somatropin (Norditropin) is a prescription medicine with an FDA approval on record since 1986. No generic is listed; pharmacies paid $752.22 per Genotropin 5 mg cartridge in the October 7, 2026 NADAC survey.
- No generic listed
- A presentation discontinued
Check it at the source: the somatropin FDA label on DailyMed (effective August 20, 2026, Eli Lilly and Company); the BLA 19640 record on Drugs@FDA; every somatropin label on DailyMed.
Highlights of the record
FDA label of August 20, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageHUMATROPE is a recombinant human growth hormone indicated for: Pediatric Patients: growth failure due to inadequate secretion of endogenous growth hormone (GH);
Forms and strengths
- 5 mg/1.5ml
- 10 mg/1.5ml
- 15 mg/1.5ml
- 30 mg/3ml
Kit; injection (solution).
On the market
- Earliest approval on file
- October 16, 1986 Humatrope, Lilly; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 6 of which 0 under generic applications, 6 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $752.22 per cartridge Genotropin 5 mg cartridge
- Shortage (FDA)
- None current 1 past records
- Recalls by its makers (FDA)
- 1 since 2016 0 Class I among all firms' recalls; latest April 27, 2016
- FAERS reports
- 72,284 through July 30, 2026
What is somatropin used for?
From the label: indications and usageHUMATROPE is a recombinant human growth hormone indicated for: Pediatric Patients: growth failure due to inadequate secretion of endogenous growth hormone (GH); short stature associated with Turner syndrome; Idiopathic Short Stature (ISS), height standard deviation score (SDS) <-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range; short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency; short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years of age. ( 1.1 ) Adult Patients: replacement of endogenous GH in adults with GH deficiency. […]
FDA pharmacologic class: Recombinant Human Growth Hormone.
Source: FDA drug label (HUMATROPE), Eli Lilly and Company, effective August 20, 2026 (SPL set a774e1ae-3997-49ee-8b0e-99a2b315d409), via openFDA; the full label on DailyMed
Is there a generic for somatropin (Norditropin)?
No generic somatropin is approved (Drugs@FDA, October 8, 2026).
- 1986 earliest approval on file
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for somatropin (Norditropin)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $752.22 per Genotropin 5 mg cartridge, up 3% from $728.29 on October 8, 2025. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Genotropin miniquick 0.2 mg (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Genotropin 12 mg cartridge | Brand | $1,810.40 per cartridge many times the lowest per-tablet cost; NADAC records the price, not why | n/a | +3% |
| Genotropin 5 mg cartridge | Brand | $752.22 per cartridge many times the lowest per-tablet cost; NADAC records the price, not why | n/a | +3% |
| Genotropin miniquick 0.2 mg | Brand | $30.90 per unit | n/a | +3% |
| Genotropin miniquick 0.4 mg | Brand | $61.64 per unit | n/a | +3% |
| Norditropin flexpro 10 mg/1.5 | Brand | $1,136.46 per mL | n/a | +4% |
| Norditropin flexpro 15 mg/1.5 | Brand | $1,704.64 per mL | n/a | +5% |
| Norditropin flexpro 5 mg/1.5 | Brand | $570.77 per mL | n/a | +5% |
| Omnitrope 5 mg/1.5 mL crtg | Brand | $430.36 per mL | n/a | +3% |
| Omnitrope 5.8 mg vial | Brand | $326.25 per vial | n/a | +0.2% |
| Zomacton 10 mg vial | Brand | $556.82 per vial | n/a | -0.7% |
| Zomacton 5 mg vial | Brand | $278.60 per vial | n/a | n/a |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Is somatropin in shortage?
No somatropin presentation is listed as in shortage in the FDA Drug Shortage Database (read October 8, 2026); its 1 record is all marked to be discontinued, the latest updated November 14, 2025. ASHP keeps a separate shortage list, which can differ.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Norditropin, Injection, 30 mg/3 mL (NDC 0169-7703-21) | Novo Nordisk, Inc. | To Be Discontinued | November 14, 2025 |
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
Has somatropin been recalled?
The FDA's Enforcement Report lists 1 recall naming somatropin since 2016: 0 Class I (the most serious), 1 Class II, 0 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| April 27, 2016 | Class II | Novo Nordisk Inc | Defective Delivery System; may have a low frequency assembly fault which may result in pens block during the so-called "air shot" step |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the somatropin label say about other medicines?
The somatropin label names 3 other medicines in its interaction, contraindication or warning sections. The labels of 18 other medicines name somatropin. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Cortisone | drug interactions | Replacement Glucocorticoid Treatment Clinical Impact: Microsomal enzyme 11β-hydroxysteroid dehydrogenase type 1 (11βHSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. HUMATROPE inhibits 11βHSD-1. … following initiation of HUMATROPE [see Warnings and Precautions ()]. Examples: Cortisone acetate and prednisone may be effected more than others since conversion of these drugs to their biologically active metabolites … |
| Cyclosporine | drug interactions | These data suggest that somatropin administration may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporine). |
| Prednisone | drug interactions | Replacement Glucocorticoid Treatment Clinical Impact: Microsomal enzyme 11β-hydroxysteroid dehydrogenase type 1 (11βHSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. HUMATROPE inhibits 11βHSD-1. … HUMATROPE [see Warnings and Precautions ()]. Examples: Cortisone acetate and prednisone may be effected more than others since conversion of these drugs to their biologically active metabolites is dependent on the … |
Other labels that name somatropin
Source: FDA drug label (HUMATROPE), Eli Lilly and Company, effective August 20, 2026 (SPL set a774e1ae-3997-49ee-8b0e-99a2b315d409), via openFDA; the full label on DailyMed
What do FAERS reports show for somatropin?
The FDA Adverse Event Reporting System holds 72,284 reports that list somatropin among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 1,365 are coded as a death and 7,048 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Reports rose sharply in 2025 (11,518, against a median of 3,639 a year): FAERS counts follow reporting, which news, litigation and label changes can drive, not how often a reaction happens.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other recombinant human growth hormones
- the pharmacologic class, with prices and generics
- Somatropin side effects
- the label's list beside FAERS reports
- Somatropin shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other